medigraphic.com
Boletín Médico del Hospital Infantil de México

2008, Number 2

<< Back Next >>

Bol Med Hosp Infant Mex 2008; 65 (2)

Evaluation of anti-arrhythmic effect of propafenone in children with supraventricular paroxistic tachycardia

Sandoval-Ramírez E, Juárez-Olguín H, Flores-Pérez C, Osnaya H, Bobadilla-Chávez J, Flores-Pérez J

Language: Spanish
References: 13
Page: 121-125
PDF size: 180.62 Kb.


ABSTRACT

Introduction. Supraventricular tachycardia (SVT) involves arrhythmias treated with propafenone in children due to its utility. The aim of this study was to evaluate the anti-arrhythmic effect of propafenone as well as its pharmacokinetics in children with SVT.
Methods. A prospective study was conducted in children with SVT. The evolution of their treatment with propafenone was followed by EKG monitoring. A pharmacokinetic study was carried out by using HPLC with fluorescence detection.
Results. The files of 85 children with SVT from 2000 to 2007 were reviewed; currently 11 patients are treated with propafenone, Pharmacokinetics study was performed in 3 of the current patients. The EKG study showed regular registers after propafenone treatment. Propafenone pharmacokinetic parameters were similar to those reported previously.
Conclusions. The patients included showed an arrhythmia remission, and their pharmacokinetic parameters were similar to those reported in the literature. Thus, the use of propafenone may be considered appropriate for SVT treatment in children.


REFERENCES

  1. Waldo AL, Wit AL. Mechanisms of cardiac arrhythmias. Lancet. 1993; 341: 1189-93.

  2. Luedtke SA, Kuhn RJ, McCaffrey. Pharmacologic management of supraventricular tachycardia in children. Ann Pharmacother. 1997; 31: 1227-43.

  3. Fitzpatrick AP, Gonzalez RP, Lesh MD, Modin GW, Lee RJ, Scheinman MM. New algorithm for the localization of accessory atrioventricular connections using a baseline electrocardiogram. J Am Coll Cardiol. 1994; 23: 107-16.

  4. Toganel R, Gozar L, Tünde N. Supraventricular tachycardia in children. Cardiol Hungar. 2002; 32: 29-33.

  5. Berne RM, Levy MN. Electrical activity of the heart. En: Berne RM, Levy MN, editores. Physiology. Third ed. St. Louis, Missouri: Mosby Year Book; 1997. p. 364-96.

  6. Ganz LI, Friedman PL. Medical progress: Supraventricular tachycardia. N Engl J Med. 1995; 332: 162-73.

  7. Vidrio H. Propafenona. En: Rodríguez R, editor. Vademécum Académico de Medicamentos. 4ª. ed. México: Interamericana McGraw-Hill; 2005. p. 687-8.

  8. Bink-Boelkens MT. Pharmacologic management of arrhythmias. Pediatr Cardiol. 2000; 21: 508-15.

  9. Batra AS, Luna CF, Silka MJ. Pharmacologic management of arrhythmias in patients with congenital heart disease. Am J Cardiovasc Drugs. 2001; 1: 91-103.

  10. Flores-Pérez C, Juárez-Olguín H, Flores-Pérez J, Ramírez-Mendiola B, Bobadilla-Chávez J. A simple method to measure plasma levels of propafenone with fluorescence detection. Chromatographia. 2005; 62: 373-7.

  11. Bauer LA. Clinical pharmacokinetics and pharmacodynamics. En: Dipiro JT, editor. Pharmacotherapy. 6th ed. USA: Editorial McGraw-Hill; 2005. p. 51-74.

  12. Wei-Min C, Yin-Di Z, Bing Ch, Ming-Hong C, Jian-Ping L, Shu-Sen L. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. Acta Pharmacol Sin. 2001; 10: 956-60.

  13. Minoo A, Mohammadreza R. A rapid HPLC assay for the simultaneous determination of propafenone and its major metabolites in human serum. Anal Sci. 2004; 20: 1307-11.




2020     |     www.medigraphic.com